Acurx Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent
Acurx Pharmaceuticals, Inc. (ACXP) reported Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent of -0.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent · last filed 2026-03-12
- Acurx Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2025 was -0.10%.
- Acurx Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2024 was -0.10%, a 106.25% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2023 was 1.60%.
- Acurx Pharmaceuticals, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2022 was -0.50%.
| Period end | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 12 month |
|---|---|
| 2025-12-31 | -0.10% 10-K · filed 2026-03-12 |
| 2024-12-31 | -0.10% 10-K · filed 2026-03-12 |
| 2023-12-31 | 1.60% 10-K · filed 2025-03-17 |
| 2022-12-31 | -0.50% 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |